School of Chemistry and Biochemistry, Institute for Bioscience and Bioengineering, Georgia Institute of Technology, 901 Atlantic Drive NW, Atlanta, GA 30332, USA.
Methods. 2011 Dec;55(4):293-302. doi: 10.1016/j.ymeth.2011.08.004. Epub 2011 Aug 11.
From G protein-coupled receptors to ion channels, membrane proteins represent over half of known drug targets. Yet, structure-based drug discovery is hampered by the dearth of available three-dimensional models for this large category of proteins. Other than efforts to improve membrane protein expression and stability, current strategies to improve the ability of membrane proteins to crystallize involve examining many orthologs and DNA constructs, testing the effects of different detergents for purification and crystallization, creating a lipidic environment during crystallization, and cocrystallizing with covalent or non-covalent soluble protein chaperones with an intrinsic high propensity to crystallize. In this review, we focus on this last category, highlighting successes of crystallization chaperones in membrane protein structure determination and recent developments in crystal chaperone engineering, including molecular display to enhance chaperone crystallizability, and end with a novel generic approach in development to target any membrane protein of interest.
从 G 蛋白偶联受体到离子通道,膜蛋白代表了已知药物靶点的一半以上。然而,基于结构的药物发现受到这一大类蛋白质缺乏可用的三维模型的阻碍。除了努力提高膜蛋白的表达和稳定性外,目前提高膜蛋白结晶能力的策略包括检查许多同源物和 DNA 构建体,测试不同去污剂对纯化和结晶的影响,在结晶过程中创建脂质环境,以及与具有固有高结晶倾向的共价或非共价可溶性蛋白伴侣共结晶。在这篇综述中,我们重点介绍了最后一类,强调了结晶伴侣在膜蛋白结构测定中的成功应用,以及晶体伴侣工程的最新进展,包括分子展示以增强伴侣的结晶能力,并以正在开发的针对任何感兴趣的膜蛋白的新型通用方法结束。